Shares of SMMT are declining approximately 9.51% in Wednesday's session on April 22, 2026, falling from a prior close of $26.38 to approximately $23.87, as investors lock in gains following the stock's sharp 16.4% single-session surge on April 21. The primary driver is profit-taking after an outsized upside move: SMMT surged from approximately $22.65 to $26.38 on April 21 on renewed investor enthusiasm surrounding ivonescimab's clinical data potential and bullish institutional commentary — gains that are now partially being retraced in the absence of a new positive catalyst.

Sutro Biopharma (STRO) stock surged +67% over the last 30 days, driven by positive preclinical data presentations and ongoing clinical advancements in its antibody drug conjugate (ADC) pipeline. Over the past quarter, shares climbed +119%, fueled by a $110 million public offering, full-year 2025 earnings release highlighting strong cash position, and key trial initiations.

SLNO stock surged +66% over the past 30 days, primarily fueled by Neurocrine Biosciences' ( NBIX ) announcement of a $2.9 billion all-cash acquisition at $53 per share. The stock rose +20% over the past quarter, recovering from mid-March lows amid positive earnings and product launch momentum before the buyout catalyst.

Jade Biosciences (JBIO) stock surged +69% over the last 30 days, driven by heightened trading volume and positive biotech sector sentiment. Over the past quarter, shares rose +47%, reflecting broader recovery and anticipation around pipeline progress.

AGIO shares fell approximately 20% in Monday's trading session, from a prior close of $35.14 on April 17, 2026, to approximately $28.11, representing one of the stock's largest single-session declines in months. The selloff coincides with the April 20, 2026, lead plaintiff deadline in a securities class-action lawsuit filed against the company, alleging potential violations of securities laws tied to disclosures surrounding Pyrukynd's clinical and regulatory development.

RLAY stock surged +69% over the past 30 days, propelled by positive clinical data updates on its lead candidate zovegalisib. Over the past quarter, shares climbed +122%, supported by an earnings beat and advancing pipeline milestones.

MapLight Therapeutics (MPLT) stock price rose +71% over the last 30 days amid strong analyst buy ratings and anticipation for Phase 2 clinical trial readouts. Over the past quarter, shares climbed +76%, supported by a robust cash position from its recent initial public offering (IPO) and positive regulatory designations.

ANL stock surged +116% over the past 30 days, driven primarily by a $150 million private placement equity financing announced mid-April. Over the past quarter, shares rocketed +765%, fueled by clinical trial advancements and multiple large financings amid positive analyst sentiment.

Crescent Biopharma (CBIO) stock surged +75% over the last 30 days, driven by fresh analyst buy ratings and sustained momentum from clinical trial advancements. Over the past quarter, shares climbed +44%, fueled by the first patient dosing in the ASCEND trial and positive full-year earnings outlook highlighting cash runway into 2028.

CG Oncology's shares have shown strong upward momentum in recent weeks, driven by clinical progress and analyst enthusiasm. Topline data from the pivotal Phase 3 PIVOT-006 trial is slated for the first half of 2026, a key catalyst for potential approval.

Relay Therapeutics (RLAY) stock surged +62% over the past 30 days, driven by positive clinical data reveals on zovegalisib, including expansions into vascular anomalies and combination therapy updates. The stock climbed +112% over the past quarter, fueled by FDA Breakthrough Therapy designation for zovegalisib in breast cancer and narrowing losses in Q4 earnings.

MGTX shares are tumbling approximately 14% in premarket trading on April 16, 2026, erasing a significant portion of a recent rally. The primary catalyst is a "sell the news" reaction following the actual release and presentation of three-year Phase 1 data for the company's AAV-hAQP1 gene therapy at an 8:00 a.m. ET investor event on April 16.

Nurix Therapeutics reported fiscal first quarter 2026 revenue of $6.3 million, down from $18.5 million a year ago due to the end of initial research terms in the Sanofi collaboration. Net loss widened to $87.2 million, or ($0.79) per share, compared to $56.4 million, or ($0.67) per share, in the prior-year quarter; EPS missed consensus estimates of ($0.76).

CLLS stock rose +18% over the last 30 days, driven by positive interim clinical data from partnered programs and strong Q4 2025 earnings beat. Over the past quarter, shares declined -5%, reflecting biotech sector volatility amid ongoing arbitration resolutions and pipeline developments.

SYRE shares surged approximately 25% in Monday's session, with the stock rising from a previous close of $51.29 to approximately $64.11 intraday. The primary catalyst is a highly positive Phase 2 SKYLINE trial readout: SPY001 met its primary endpoint with a statistically significant 9.2-point reduction in Robart's Histopathology Index (RHI) score (p<0.0001) at Week 12 in moderate-to-severely active ulcerative colitis patients.

Shares of Revolution Medicines (RVMD) surged +37.33% in today's session, rising from a prior close of $96.43 to $132.43, with an intraday high of $135.81. The primary catalyst is a landmark Phase 3 clinical trial win: daraxonrasib nearly doubled median overall survival versus standard chemotherapy in second-line metastatic pancreatic ductal adenocarcinoma (PDAC)

ERAS shares declined approximately -12% intraday on Monday, April 13, 2026, pulling back sharply from a recent 52-week high of $18.20 reached on April 7. The selloff appears primarily driven by profit-taking and valuation pressure after a staggering ~1,497% rally over the past twelve months, with shares trading well above most pre-run analyst consensus targets.

Replimune Group (REPL) shares collapsed approximately 63.24% in premarket trading on Monday, April 13, 2026, falling from a Friday close of $4.76 to around $1.75. The primary catalyst is the FDA's second consecutive Complete Response Letter (CRL) issued April 10, 2026, rejecting the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.

LEXX stock rose +24% over the last 30 days, driven by positive GLP-1 clinical study announcements and sector momentum in oral drug delivery. Over the past quarter, the stock gained +12%, supported by Q1 earnings beat, reduced losses, and new patent awards.

TERN stock rose approximately +18% over the last 30 days, primarily driven by Merck's March 25 announcement of a $53 per share acquisition deal, representing a substantial premium to prior trading levels. Over the past quarter, shares surged +48%, fueled by building momentum in oncology pipeline updates and culminating in the transformative buyout agreement.